Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Eptinezumab

            Therapeutic Area: Neurology Product Name: Vyepti

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 15, 2021

            Details:

            Patients receiving VYEPTI reported a median time to headache pain freedom of 4 hours vs. 9 hours among those who received placebo, and a median time of 2 hours to the absence of their MBS vs. 3 hours with placebo.